Skip Nav Destination
CART19 in Hodgkin lymphoma: are we driving the right model?
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
Nonviral RNA chimeric antigen receptor–modified T cells in patients with Hodgkin lymphoma
Issue Archive
Table of Contents
BLOOD COMMENTARIES
CLINICAL TRIALS AND OBSERVATIONS
CART19 in Hodgkin lymphoma: are we driving the right model?
Clinical Trials & Observations
PLENARY PAPER
PERSPECTIVE
BLOOD SPOTLIGHT
CLINICAL TRIALS AND OBSERVATIONS
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
Clinical Trials & Observations
David J. Straus,Sin-Ho Jung,Brandelyn Pitcher,Lale Kostakoglu,John C. Grecula,Eric D. Hsi,Heiko Schöder,Leslie L. Popplewell,Julie E. Chang,Craig H. Moskowitz,Nina Wagner-Johnston,John P. Leonard,Jonathan W. Friedberg,Brad S. Kahl,Bruce D. Cheson,Nancy L. Bartlett
Nonviral RNA chimeric antigen receptor–modified T cells in patients with Hodgkin lymphoma
Clinical Trials & Observations
Brief Report
Jakub Svoboda,Susan R. Rheingold,Saar I. Gill,Stephan A. Grupp,Simon F. Lacey,Irina Kulikovskaya,Megan M. Suhoski,J. Joseph Melenhorst,Brandon Loudon,Anthony R. Mato,Sunita Dwivedy Nasta,Daniel J. Landsburg,Matthew R. Youngman,Bruce L. Levine,David L. Porter,Carl H. June,Stephen J. Schuster
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL
Sean D. Reiff,Elizabeth M. Muhowski,Daphne Guinn,Amy Lehman,Catherine A. Fabian,Carolyn Cheney,Rose Mantel,Lisa Smith,Amy J. Johnson,Wendy B. Young,Adam R. Johnson,Lichuan Liu,John C. Byrd,Jennifer A. Woyach
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92
Eugenio Morelli,Lavinia Biamonte,Cinzia Federico,Nicola Amodio,Maria Teresa Di Martino,Maria Eugenia Gallo Cantafio,Martina Manzoni,Francesca Scionti,Mehmet Kemal Samur,Annamaria Gullà,Maria Angelica Stamato,Maria Rita Pitari,Daniele Caracciolo,Settimio Sesti,Niels M. Frandsen,Marco Rossi,Antonino Neri,Mariateresa Fulciniti,Nikhil C. Munshi,Pierosandro Tagliaferri,Pierfrancesco Tassone
THROMBOSIS AND HEMOSTASIS
Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway
Coline Haxaire,Narine Hakobyan,Tania Pannellini,Camila Carballo,David McIlwain,Tak W. Mak,Scott Rodeo,Suchitra Acharya,Daniel Li,Jackie Szymonifka,Xiangqian Song,Sébastien Monette,Alok Srivastava,Jane E. Salmon,Carl P. Blobel
von Willebrand factor enhances microvesicle-induced vascular leakage and coagulopathy in mice with traumatic brain injury
Yingang Wu,Wei Liu,Yuan Zhou,Tristan Hilton,Zilong Zhao,Wei Liu,Min Wang,Jason Yeon,Katie Houck,Perumal Thiagarajan,Fangyi Zhang,Fu-Dong Shi,Xiaoping Wu,Min Li,Jing-fei Dong,Jianning Zhang
BLOOD WORK
-
Cover Image
Cover Image
Hemophilic arthropathy (HA) is a major cause of disability in hemophilia A patients. The authors show that tumor necrosis factor-α and its upstream regulators, iRhom2 and ADAM17, have a pivotal role in synovitis and bone loss in HA. This is evidenced by osteoclasts (red) resorbing bone (blue). See the article by Haxaire et al on page 1064.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals